

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 May 2018 (24.05.2018)

(10) International Publication Number
WO 2018/093946 A1

(51) International Patent Classification:

C07D 498/08 (2006.01) C07D 403/04 (2006.01)
C07D 471/10 (2006.01) C07D 295/26 (2006.01)
C07D 295/205 (2006.01)

(21) International Application Number:

PCT/US2017/061867

(22) International Filing Date:

15 November 2017 (15.11.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/423,095 16 November 2016 (16.11.2016) US

(71) Applicant: ABIDE THERAPEUTICS, INC. [US/US];
10835 Road to the Cure, Suite 250, San Diego, California
92121 (US).

(72) Inventors: GRICE, Cheryl A.; 924 Springwood Lane,
Encinitas, California 92024 (US). BUZARD, Daniel J.;
14494 Janal Way, San Diego, California 92129 (US).
WHITE, Nicole S.; 3672 Caminito Cielo Del Mar, San
Diego, California 92130 (US). HERTZOG, Donald L.;
114 Ashworth Drive, Durham, North Carolina 27707 (US).

(74) Agent: HOSTETLER, Michael J.; WILSON SONSINI
GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto,
California 94304 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: MAGL INHIBITORS

(57) Abstract: Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.



WO 2018/093946 A1